Equities analysts expect Iovance Biotherapeutics Inc (NASDAQ:IOVA) to announce ($0.35) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Iovance Biotherapeutics’ earnings, with the highest EPS estimate coming in at ($0.18) and the lowest estimate coming in at ($0.43). Iovance Biotherapeutics posted earnings of ($0.36) per share during the same quarter last year, which indicates a positive year over year growth rate of 2.8%. The business is expected to announce its next earnings report on Tuesday, November 5th.

According to Zacks, analysts expect that Iovance Biotherapeutics will report full-year earnings of ($1.38) per share for the current year, with EPS estimates ranging from ($1.60) to ($0.84). For the next year, analysts anticipate that the business will report earnings of ($1.54) per share, with EPS estimates ranging from ($2.41) to ($0.59). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Iovance Biotherapeutics.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its earnings results on Thursday, August 1st. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.09).

IOVA has been the topic of several recent analyst reports. Robert W. Baird raised their target price on shares of Iovance Biotherapeutics from $29.00 to $34.00 and gave the stock an “outperform” rating in a report on Thursday, May 16th. ValuEngine upgraded shares of Iovance Biotherapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, May 23rd. UBS Group raised their target price on shares of Iovance Biotherapeutics from $25.00 to $30.00 and gave the stock an “outperform” rating in a report on Monday, June 3rd. B. Riley set a $24.00 target price on shares of Iovance Biotherapeutics and gave the stock a “buy” rating in a report on Friday, May 17th. Finally, Zacks Investment Research upgraded shares of Iovance Biotherapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Iovance Biotherapeutics has an average rating of “Buy” and an average price target of $28.45.

Several hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC bought a new stake in shares of Iovance Biotherapeutics during the 2nd quarter valued at $29,000. Edge Wealth Management LLC boosted its holdings in shares of Iovance Biotherapeutics by 20.2% during the 2nd quarter. Edge Wealth Management LLC now owns 8,414 shares of the biotechnology company’s stock valued at $207,000 after buying an additional 1,414 shares in the last quarter. Advisor Group Inc. boosted its holdings in shares of Iovance Biotherapeutics by 58.6% during the 4th quarter. Advisor Group Inc. now owns 8,118 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 3,000 shares in the last quarter. Aperio Group LLC bought a new stake in shares of Iovance Biotherapeutics during the 2nd quarter valued at $86,000. Finally, Swiss National Bank boosted its holdings in shares of Iovance Biotherapeutics by 2.3% during the 2nd quarter. Swiss National Bank now owns 195,200 shares of the biotechnology company’s stock valued at $4,786,000 after buying an additional 4,400 shares in the last quarter. Hedge funds and other institutional investors own 95.67% of the company’s stock.

Shares of Iovance Biotherapeutics stock traded down $0.50 on Thursday, hitting $20.02. The stock had a trading volume of 1,322,889 shares, compared to its average volume of 1,447,800. The company has a debt-to-equity ratio of 0.01, a quick ratio of 12.14 and a current ratio of 12.15. Iovance Biotherapeutics has a one year low of $7.26 and a one year high of $26.59. The firm has a market cap of $2.52 billion, a PE ratio of -15.76 and a beta of 1.81. The firm has a 50-day moving average of $23.98.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma.

Featured Article: Trading signals using Bollinger bands

Get a free copy of the Zacks research report on Iovance Biotherapeutics (IOVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Iovance Biotherapeutics (NASDAQ:IOVA)

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.